Anzeige
Mehr »
Login
Dienstag, 19.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Solarbetriebenes Krypto-Mining: Die Strategie, die diese Aktie um 75?% steigen ließ!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
364 Leser
Artikel bewerten:
(1)

Empowered Diagnostics Receives CE Mark for CovClear COVID-19 Rapid Antigen Test

Finanznachrichten News

POMPANO BEACH, Fla., April 20, 2021 /PRNewswire/ -- Empowered Diagnostics LLC, one of the largest U.S.-based manufacturers of rapid diagnostic testing solutions, announced today that it received CE marking for its CovClear COVID-19 Rapid Antigen Test.

CovClear is a lower-cavity nasal swab test that can detect active COVID-19 infection within about two days of exposure to SARS-CoV-2, before a person becomes contagious. The test produces highly accurate results within minutes, and is quick, comfortable and simple to use. It has been researched, developed and manufactured in the U.S., and is produced using the highest quality materials available.

"We are empowering people worldwide with the knowledge and confidence to understand their health," said Barry Abraham, President of Empowered Diagnostics. "CovClear receiving a CE mark is an important step in delivering access to extremely accurate, affordable rapid testing throughout the European Union. We are proud to lead the global effort in raising the bar for high-sensitivity diagnostic tests."

CovClear has 99.7% accuracy, 98.5% sensitivity and 100% specificity.

"Highly sensitive tests are essential for preventing the spread of COVID-19 by minimizing false negatives and, therefore, the false confidence delays that discourage people from re-testing," Abraham said.

With a manufacturing capacity of 20 million tests per month, Empowered Diagnostics is uniquely equipped to deliver critically needed tests worldwide. In addition to CovClear, the company developed the ImmunoPass COVID-19 Neutralizing Antibody Rapid Test, which measures levels of virus-neutralizing antibodies that indicate immunity.

CovClear was developed and engineered for at-home testing. FDA Emergency Use Authorization, in addition to authorization in the United Kingdom and Canada, is anticipated in the coming weeks. Empowered Diagnostics is working closely with the FDA to secure over-the-counter designation for CovClear. Tests are currently used in the U.S. for corporate surveillance and self-screening programs, ensuring that employees remain safe and healthy as they head back to the office. The CovClear test will be available at doctors' offices, pharmacies and other point-of-care locations throughout the European Union.

About Empowered Diagnostics
Empowered Diagnostics delivers innovative, best-in-class diagnostic tests backed by leading experts in healthcare and biotechnology. Our mission is to empower people with the knowledge and confidence to understand their health through reliable, affordable, high-quality tests. Based in Pompano Beach, Florida, Empowered Diagnostics is one of the largest U.S.-based manufacturers of rapid diagnostic solutions.

Media Contact:
Emily Greifeld
RF|Binder
emily.greifeld@rfbinder.com
212-994-7633

© 2021 PR Newswire
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.